Company Comparison
Forty Seven vs 23andMe
Side-by-side comparison of two portfolio companies — sector, funding stage, investors, valuation, and more.
| Metric | Forty Seven | 23andMe |
|---|---|---|
| Sector | Biotech | Biotech |
| Headquarters | Menlo Park, California | South San Francisco, California |
| Founded | 2014 | 2006 |
| Status | Active | Active |
| Last Funding Stage | Series C | — |
| Total Funding | $320M | — |
| Valuation | — | — |
What They Build
Forty Seven
Biotechnology company developing cancer immunotherapies targeting the CD47 pathway to enhance immune system recognition of cancer cells.
23andMe
23andMe Holding Co. is an American personal genomics and biotechnology company based in South San Francisco, California.
Key Investors
Forty Seven
Sector Overlap
Both Forty Seven and 23andMe operate in Biotech.
Browse all Biotech companies →Websites
Sponsored
AArchstone
The operating system for private capital.
Archstone runs the back office for venture, PE, real estate, and credit funds — LP reporting, capital calls, portfolio tracking, and fund accounting, in one platform. Now in alpha.
LP portal & reportingCapital callsPortfolio tracking$297/moNo AUM fees
Now in alpha with select funds. 14-day trial available.